

## Conceptual Approaches to Alternate Methods in Toxicological Testing

Alan M. Goldberg

*The Johns Hopkins School of Hygiene and Public Health,  
Baltimore, MD 21205, USA*

Andrew N. Rowan

*Tufts School of Veterinary Medicine, Boston, MA 02111, USA*

### ABSTRACT

Due to public pressure, *in vivo* methods of toxicity testing is being attempted to be replaced by *in vitro* methods, such as cell and organ culture, computer modelling and modified LD<sub>50</sub> tests using lesser number of animals. Specifically in the case of Draize eye irritancy test using rabbits, a number of refinements have been incorporated by different workers, mainly use of a local anaesthetic which will reduce animal distress without vitiating the test results. The author recommends exploration of new avenues for testing based on the advances in cell biology.

### 1. INTRODUCTION

There is a societal need and responsibility for public authorities to attempt to ensure that individuals in society are protected from harmful effects of foreign substances. Given the current state of our knowledge, this necessitates some testing in animals and extrapolation of the results, no matter how difficult, to predict likely human responses. We are still far too ignorant to predict the toxic effects of a compound from first principles (via theoretical toxicology?). Therefore, we have to fall back on appropriate models of the human system to identify possible hazards. By necessity, this leads to the use of mammals or other species that often respond in a sufficiently similar manner to humans to provide an index of the potential hazard.

---

Received 1 December 1986

Reproduced, with permission, from the Annual Review of Pharmacology & Toxicology, Vol 25, ©, 1985 by Annual Reviews Inc.

Nevertheless, the problems of extrapolation and evaluation are formidable. Thousands of new chemicals need to be evaluated every year while only a fraction of the estimated 65,000 chemicals<sup>1</sup> in common use today have been subject to testing according to available public information.<sup>2</sup> In addition, the present animal testing technologies are generally crude, cumbersome and costly and there is growing public criticism of such use of animals.

Among toxicologists, there are some who see animal testing as an unsatisfactory answer to toxicology's problems. Thus, in 1971, Rofe,<sup>3</sup> in an excellent but little-cited review of the use of tissue culture in toxicology, stated that:

'In seeking to bridge the gap between the effects of foreign substances on animals and their effects on man, it seems unlikely that a substantial contribution to the problem can be made by prolonging the conventional toxicological procedures or including additional organ function tests'.

Others, scientific and non-scientific, have also criticized animal testing,<sup>3-9</sup> commenting variously that toxicology has, in the last decade, sometimes created more problem than it has solved, that toxicology is a science without scientific underpinning, and that we should move towards the development of an appropriate battery of short term tests, using both *in vitro* and *in vivo* approaches, to assess product safety.

The techniques most commonly highlighted as having potential for the future are cell and organ culture, computer modelling, and the use of less invasive animal procedures and endpoints producing little stress or suffering. There have already been a number of reviews of the use of cell and organ culture in toxicology investigations beginning with a seminal paper by Pomerat and Leake in 1954,<sup>10</sup> followed by a number of reviews after 1970.<sup>3,11-20</sup> However, judging from the number of citations to these papers, none have had impact. According to the records of the Science Citation Index, Rofe's 1971 review has been cited less than twenty times in the following 12 years with a high of three citations each in 1976 and 1980. Although more and more toxicological research is being conducted *in vitro*, the potential of cell culture, as applied to toxicological evaluation and hazard assessment, is only now beginning to be tested and assessed. This is the result of public pressure, the availability of funds for such studies, and increased concern among scientists.

However, the use of cell cultures must be cautiously developed and implemented in toxicology testing and hazard assessment. Obviously, a single cell culture cannot mimic all the complex interactions of all the cell types in the body no matter how exquisite the experimental design. *In vivo* metabolism may be simulated to some extent but not completely<sup>21</sup> and other integrating functions (for example, hormones, immune reactions, phagocytosis) are not included. In addition, a cell culture is a relatively static system in which the dose of the test chemical reaching the target system and the duration of contact may not be the same as those that occur in the *in vivo* tests. There are also physical problems regarding solubility, stability and biophysical effects of the test compound.

On the other hand, the technique of cell culture has great potential once investigators have acquired the background knowledge to ask highly focused and

specific questions. The static nature of cell culture is also an advantage in that the dose and duration of contact of a test chemical can be precisely determined. Far less of the test chemical is required for cell culture investigations than in *in vivo* tests. Therefore, one can set up replicate cultures with ease and generate more data in a short time.

One of the most exciting aspects of cell culture studies in toxicology is that one can use human tissue. Such studies have been limited in the past because of the difficulty of maintaining and growing differentiated human cell types in culture. But, the technical problems are being steadily overcome. For example, important developments in the past years include improvements in the quality control of media and plasticware provided by manufacturers, improved quality control in the laboratory, better media formulations<sup>22</sup> for the growth of normal cells as well as for cells exhibiting specialized functions (for example, heart cell contractility and melanin production by melanocytes), and improvements in cell separation and cloning techniques.<sup>23</sup>

Nardone and Bradlaw<sup>23</sup> describe four interfaces between *in vitro* methodology and animal toxicology – screening tests, mechanistic studies, personnel monitoring and considerations for risk assessment. They note that screening tests are the most developed and are likely to remain the major focus of *in vitro* toxicology. However, mechanistic studies probably will become steadily more important, both in toxicological evaluations and for risk assessment. One could also classify *in vitro* methodology according to whether the approach is empirical, model development or mechanistic.<sup>24</sup>

The empirical approach for the development of methodology is problematic. The questions asked are generally not focused and the intent is to develop correlations prior to fundamental understandings. Additionally, the results tend to be somewhat unpredictable. Should this be the case in the development of *in vitro* toxicological methods we will have unfortunately provided supplementary testing strategies but not replacement testing strategies. This will leave us with the dilemma of attempting to use the *in vitro* methodologies without being able to rely on them.

Model development attempts to utilize systems that mimic the *in vivo* systems. Generally, the model system is neither complete nor faithful in all aspects of the system being modeled, but it tends to provide useful information if the data are not over-interpreted. In those model systems where a single aspect of an integrated response is examined and the data are interpreted in that single system, it can provide meaningful inferences for the evaluation of chemical effects.

The mechanistic approach in the development of *in vitro* methodologies should be based on a thorough knowledge of the metabolism, kinetics, and biology in the system or species to be examined. If the metabolic pathways are understood, or if it is known that the parent compound produces the toxicological insult, then one can develop a system to examine the mechanisms by which the chemical(s) works. That is, one can examine the adverse chemical or physical effects that lead to a significant functional loss in the tissue or system. This approach allows the *in vitro* system to be derived from the species under study. It also provides a better understanding of the chemical-biological interaction and the consequences of that interaction. Once a

mechanism has been identified it may then be possible to develop appropriate, interpretable, simple and reliable *in vitro* methodologies.

From a scientific viewpoint, the mechanistic approach is not only preferable but necessary. *In vitro* methods will be more acceptable and will develop rapidly when the knowledge base has advanced far enough to permit a focus on mechanisms.

## 2. ALTERNATIVES IN TOXICOLOGY

Toxicity testing on animals may be divided into acute, subacute and chronic tests. Acute tests are those in which the animals are dosed with one or a few doses of the test compound and kept for at most a few weeks. Such tests include protocols for determining the various LD<sub>50</sub>'s as well as eye and skin irritancy tests. Up to 50 per cent of all animals used in toxicology testing are killed in acute tests.<sup>25</sup> Subchronic tests last from a few weeks to several months. Chronic tests last for more than three months and include tests for reproductive and carcinogenic effects among others. The search for new approaches in all these areas will continue to evolve. However, at present time, our lack of knowledge about the mechanisms of possible toxic insults is such that some animal testing is going to be required.

### 2.1 Acute Toxicity Testing

In acute tests, the investigator is observing an immediate response in which the organism's defence mechanisms are rapidly overwhelmed. Where specific end-points are being determined (for example, eye irritancy) it may well be possible to develop an adequate *in vitro* alternative based on one or more screening systems. However, one of the functions of acute testing is the identification of unexpected toxic effects. The empiricism of this approach requires that a relatively good model for the whole human being be used. This generally means using a whole mammal because the metabolism and response of other mammals is at least sufficiently similar to human responses to provide an index of hazard. However, there are acute tests for which the prospect of either reducing the number of animals used, or for developing an adequate *in vitro* tests are relatively good and these are discussed below.

#### 2.1.1 LD<sub>50</sub> testing

The calculation of the median lethal dose LD<sub>50</sub> for the measurement of toxicity was introduced<sup>26</sup> in 1927. At that time, determination of the LD<sub>50</sub> was used to standardize such potent biologicals as digitalis, insulin and diphtheria toxin. With time, however, the LD<sub>50</sub> came to be used as a standard measure by which the toxicity of all chemicals was assessed. In 1968, Morrison, Quinton and Reinert questioned this use<sup>27</sup> of the LD<sub>50</sub>, arguing that the classical test used too many animals and that the statistical figure resulting was quite meaningless. They contended that a figure, generated from the use of 6-10 animals, was the best that could be achieved given the inadequacies of the test system.<sup>28</sup> There have been several recent criticisms<sup>29-31</sup> of the LD<sub>50</sub>. As a result of scientific criticism, coupled with political pressure from the

animal welfare movement, the classical LD<sub>50</sub> test (with a few specific exceptions) appears to be on its way out as a regulatory requirement. For example, the German authorities are accepting acute toxicity test data using small number of animals<sup>32,33</sup> and the Food and Drug Administration has now explicitly stated that it has no requirement for LD<sub>50</sub> tests and that acute toxicity data from alternative tests may well be acceptable.<sup>34</sup>

The alternatives that are being considered all require the use of far fewer animals. Bruce<sup>35</sup> has proposed the use of six to ten animals in the Up-Down method<sup>36</sup> although it cannot be recommended for testing materials where delayed deaths (more than a few days) are the rule. Several simplifications of the standard method, all of which require fewer animals, have recently been proposed<sup>37-40</sup> and the last,<sup>40</sup> which recommends the use of only 13 animals, is claimed to be suitable for industrial use where a variety of chemicals of widely differing toxicities must be assessed. Where only an estimate is required, the method proposed by Deichmann and LeBlanc offers yet another choice.<sup>41</sup>

Another approach which has also been suggested, is the use of a structure-activity computer model to estimate<sup>42,43</sup> LD<sub>50</sub>'s. This approach has been criticized because the chemicals used to design the models were not congeneric and because the biological end-point (death) used is not the function of a single active site in a well-defined system.<sup>44</sup> The developers of the model argue that there is no question that the use of a congeneric set of chemicals would produce tighter estimates but that this is insufficient reason not to explore a model based on heterogenous collections of chemicals. As this field of quantitative structure-toxicity relationships (QSTR) develops, one can anticipate major strides in the use of these systems as predictors of toxicity.<sup>45</sup>

There have been several papers which have correlated the results of cytotoxicity assays with animal<sup>46-50</sup> LD<sub>50</sub>'s, but the development of an adequate cell culture alternative is very unlikely. There are many different toxic effects, and a crude cytotoxicity assay is unlikely to be successful as a general screen for acute toxicity. In addition, these non-mechanistic tests may result in the identification of an excessive number of false-positives and false-negatives and efforts to correlate cytotoxicity data with questionable LD<sub>50</sub> figures are unlikely to yield significant toxicological insights. Nevertheless, there is a clear need for good cytotoxicity data and for the development of reliable measures of cytotoxicity.<sup>47-50</sup>

Therefore, the present state of development of alternative approaches to the classical LD<sub>50</sub> test is focused on the use of fewer animals (up to a 90 per cent reduction) with more attention being paid to morbidity and symptoms than a statistical estimate of the median lethal dose. For most purposes, the use of small numbers of animals to estimate the median lethal dose appears to be a satisfactory alternative. Cell culture systems have been investigated but they cannot provide the breadth of coverage of possible toxic insults of a simple *in vivo* mammalian organism. A computer model for estimating LD<sub>50</sub>'s has been developed.<sup>42</sup> While it allows one to estimate the toxicity of a new substance quickly, the computer model suffers limitations as a possible replacement to the animal test.

### 2.1.2 Ophthalmic irritancy testing

The classic method for assessing the potential for ophthalmic irritancy of chemicals is the Draize Eye Irritancy test.<sup>51,52</sup> In recent years this test has been criticized by both scientists<sup>53,54</sup> and by animal welfare groups.<sup>55</sup> In fact, in 1978, Smyth commented that the Draize Eye Irritancy test was one area where a search for a non-animal alternative had a real chance of success.<sup>56</sup> A recent review of eye irritation testing outlines some of the difficulties in identifying eye irritants and the specific historical background of, and problems with the Draize Eye Irritancy test.<sup>57</sup> For example, one of the main difficulties with this test as a regulatory tool is identified as the subjective nature of scoring and evaluating the test response.

Pressure from animal welfare campaigns has, in recent years, resulted in the support of a number of projects to seek an alternative to the Draize Eye Irritancy test with promising results. The projects can be divided into those investigating modifications of the test which would result in less animal distress, and those investigating *in vitro* and protozoan systems as possible replacements.<sup>23</sup>

(i) *Refinements to the classical draize eye irritancy test:* The test modifications which have been proposed include the use of smaller volumes,<sup>54</sup> which would reduce the severity of the reaction as well as permitting the investigator to develop dose-response curves, the use of local anaesthetics,<sup>57</sup> an exfoliative cytology test which is reportedly more sensitive and more easily quantified than the classic Draize Eye Irritancy test,<sup>58</sup> and the identification of all severe dermal irritants as eye irritants without further testing. Griffith and his colleagues have argued, with some justification, that the use of a single 100  $\mu$ l aliquot for eye irritation testing is inappropriate. They suggest that a 10  $\mu$ l aliquot (and higher multiples) is retained in the eye better and that dose-response curves can be developed if necessary.<sup>54</sup> In most cases, the use of smaller quantities of material being placed in the eye will result in less irritation and therefore less animal distress.

In recent years, there have been several investigations of the use of local anaesthetics in the eye during ophthalmic testing as a means of reducing animal suffering. Ulsamer has reported that butacaine sulfate provided adequate anaesthesia without notably affecting the irritancy scores.<sup>59</sup> Hoheisel (personal communication, 1984) indicates that a double dose of tetracaine (separated by 10 minutes) is more effective in abolishing pain and interferes less with the irritant response, although Walberg disputes this.<sup>58</sup> Johnson reports that amethocaine HCl is also effective. In a trial of thirty one substances, the anaesthetic ether had no effect, or produced an increase in the irritant response and did not, therefore, mask irritancy.<sup>60</sup>

Walberg has developed a very promising modification to the Draize Eye Irritancy test which is less stressful to the animal, more sensitive and more easily quantified.<sup>58</sup> The eye is exposed to the test substances and then, at standard intervals after the exposure, exfoliated cells are retrieved from the conjunctival sac via a distilled water rinse. The number of cells retrieved is a very sensitive index of irritancy and correlates well with published Draize Eye Irritancy test scores. The approach needs further validation but appears to be promising as a more sensitive and more objective approach

to eye irritancy testing. The greater sensitivity of the exfoliative cytology test also means that smaller or more dilute doses of irritant substances could be used, thereby causing less trauma and distress.

It has also been suggested that a rapid and simple approach to the elimination of most severe irritants from eye testing, and to reduce the number of rabbits required, would be to pre-test materials for primary skin irritation or other properties. However, Williams<sup>61</sup> reports that of 60 materials that were found to be severe primary skin irritants or corrosive to the skin, and that has also been tested for primary eye irritancy, only 34 were severe eye irritants. Fifteen of the 60 were only mildly irritating or non-irritants in the eye test. Williams cautions, therefore, that it may be misleading to classify a substance as an eye irritant solely on the basis of dermal irritancy. He suggests that the 24 hour occlusion method used in skin testing may well overwhelm physiological defence mechanisms. The lack of correlation between dermal and ophthalmic scores may be due to overestimation of the dermal response by current test procedures. In regards to other properties such as pH, substances with a pH of 12 or more are usually regarded as eye irritants. However, Murphy and colleagues<sup>62</sup> caution that there is no simple rule for predicting irritancy from the pH. Acetic acid (5 percent), with a pH of 2.7, produces substantial corneal opacity while 0.3 percent hydrochloric acid (pH of 1.3) causes no corneal opacity. At the other end of the scale, 2.5 percent ammonium hydroxide (pH 11.8) produced corneal opacity while 0.3 percent sodium hydroxide (pH 12.8) did not. Nevertheless, Walz<sup>63</sup> reports a clear relation between irritation (oedematous reaction after intracutaneous injection) and pH in a mouse skin test of tissue compatible buffers. Buffers with a pH of below 3 and above 11.5 caused irritation. The boundary for the alkalis was very sharp.

(ii) *Replacement methods for the classical Draize Eye Irritancy test:* A wide range of *in vitro* and protozoan systems have been proposed as possible alternatives (at least as preliminary screens) for the Draize Eye Irritancy test. Nardone and Bradlaw<sup>23</sup> have already reviewed many of these including the use of enucleated eyes (rabbit), human or rabbit corneal cell cultures, other types of cell cultures, and the chorioallantois of chick embryos. Some of the first attempts to devise a specific alternative to the Draize Eye Irritancy test were undertaken in Britain using mouse<sup>64</sup> or human buccal mucosa cells.<sup>65</sup> The authors of both reports indicated that the *in vitro* approach showed promise but that much more work would be needed to develop and validate an adequate test system. While there have been a spate of recent research reports<sup>66-78</sup> from investigators seeking an alternative to the Draize Eye Irritancy test, there is still no clear indication of which approach might be the most effective.

Cytotoxicity and cell morphology studies appear to be the favoured approach but few of the studies have gone beyond a characterization of the *in vitro* system. Douglas and Spilman chose to develop a human ocular cell culture as an *in vitro* assay since it would retain species-specific and organ-specific characteristics.<sup>75</sup> They chose corneal tissue since corneal damage is the most heavily weighted in scoring damage in the Draize Eye Irritancy test. They further required that the test system should be practical for routine use and that the assay be based on cell perturbations which are relevant

to *in vivo* irritation (e.g.  $^{51}\text{Cr}$  release, LDH release), uptake of AIB (a non-metabolized amino acid), and rhodamine uptake as an index of mitochondrial function. Although the preliminary results from  $^{51}\text{Cr}$  release were promising, the project was unfortunately not completed.

While Douglas and others have favoured the idea of using corneal cells to match, as far as is possible, organ-specific characteristics, Borenfreund<sup>71</sup> reports that cells from different organs and species appear to give very similar results, indicating that it may not be that important to match cell culture type with the target organ. The results of Borenfreund's cytotoxicity and morphology assay indicate reasonable correlation with Draize Eye Irritancy test scores and also with another possible alternative based on a cellular uridine-transport assay developed in the same laboratory.<sup>70</sup>

Another approach has involved the use of whole enucleated rabbit<sup>69</sup> or bovine<sup>77</sup> eyes. Burton *et al.* report that the enucleated eyes remain viable for at least four hours and that there is good correlation of the results from this system (using a measurement of corneal swelling) with *in vivo* eye irritancy.<sup>69</sup> However, although these whole eye systems may be useful as predictors of human eye irritation. Douglas argues that they are poorly suited to the screening of a large number of compounds or of many replicate samples.<sup>75</sup>

It has been suggested that cell culture systems are not well suited to predicting how fast the eye might recover from the toxic insult. However, Chan<sup>67</sup> is working with a corneal cell culture system which might be used to predict recovery from injury and Jumblatt and Neufeldt<sup>79</sup> have described a cell culture model for wound closure studies.

Two other *in vitro* models using the chick chorioallantoic membrane<sup>72</sup> (CAM) and excised guinea pig ileum<sup>73,74</sup> have also been reported recently. Leighton is developing the CAM from the chick embryo as a non-sentient but intact organ which could be used to evaluate irritation and inflammation.<sup>72</sup> The initial reports are based on tests conducted with fairly strong acid and alkali solutions and measurement of the size of the resultant lesion. This is an end-point which requires refinement. There have also been problems from background irritation caused by shell fragments falling on the CAM when the aperture is cut. Nevertheless, the CAM system could be a very promising model for modelling inflammatory responses provided a simple but elegant end-point can be developed.

Many new model systems have been investigated in the past few years and some already show considerable promise as improvements on the Draize Eye Irritancy test or as the basis for rapid screening systems. However, at the present time, none of the *in vitro* systems have yet been sufficiently validated or evaluated to be considered as replacements to the classical or modified Draize Eye Irritancy test.

### 2.1.3 Dermal toxicity testing

Some of the same approaches applied to the search for alternatives to ophthalmic irritancy testing would probably be successful for dermal irritancy testing. There are

difficulties in extrapolating from animal to humans.<sup>80,81</sup> However, very little research into possible *in vitro* systems for identifying skin irritants has, so far, been undertaken. There have been isolated reports of the use of *in vitro* skin cultures to study toxic reactions or mechanisms<sup>82,83</sup> but there has been no concerted programme to seek an *in vitro* screening test for irritancy and cutaneous toxicity. Another area of dermal toxicity is phototoxicity which is now routinely evaluated in animals. Several alternative methods have been investigated<sup>84-87</sup> but are still at a relatively early stage of development.

#### 2.1.4 Other organs

One area of acute toxicity where alternative methods may be expected to contribute to our understanding of potential chemical insult concerns the acute reactions of isolated organs or cell cultures to large doses such as might occur during unintentional exposures. The setting of public emergency limits and the development of appropriate therapies for acute poisoning cases could find data derived from *in vitro* organotypic systems to be invaluable. Little attention has been paid to this area of acute organ toxicity.

### 2.2 Chronic Toxicity Testing

In chronic toxicity testing, where the investigator is assessing the likelihood for both targetted (for example, carcinogenicity) and non-targetted (for example, disorder in lipid metabolism) effects, we are much more likely to be able to predict human hazards if we understand the mechanism of the toxic insult than if we continue to rely on empirical testing approaches. In the acute toxicity field discussed above, there has been a focused, funded effort to find alternatives following both empirical, and mechanistic lines. In chronic toxicity testing, a similar effort is underway to develop short-term tests to identify mutagens, carcinogens and teratogens, but not to investigate organ-specific effects.

## 3. CONCLUSION

This brief review of alternative approaches to acute toxicity tests and eye irritancy testing provides an introduction to some new conceptual approaches to toxicology testing. A simple empirical search for *in vitro* tests that correlate with various toxic end-points will not only be insufficient, it will be detrimental. The possibility of developing superior methods for safety evaluation is much more likely to be realized if mechanistic approaches are used when investigating *in vitro* tests. For cell cultures, both animal and human, to be used to their full potential, the culture techniques must be considerably improved. Fully defined growth media must be developed which will support the growth of a wide range of defined cells. It is now possible to maintain and grow many different types of cells which express differentiated function *in vitro*. For example, changing culture conditions allowed one group of investigators to establish a thyroid cell line which expressed differentiated thyroid cell characteristics

even after three years of continuous culture.<sup>88</sup> Also, beating heart cells can be maintained for a week in good condition and have been used to investigate anaesthetic<sup>89</sup> and isoproterenol<sup>90</sup> cardiotoxicity.

Computer-assisted structure-activity relationships in toxicology have not yet been developed. As toxicology databases and our understanding of mechanisms improve, so will the potential applicability of quantitative structure-toxicity relationships.<sup>45,91,92</sup>

With the exciting advances now taking place in the disciplines that contribute to toxicology (for example, molecular biology, cell biology), the time is opportune for academic, industrial and regulatory toxicologists to explore new avenues for safety evaluation. This will mean discarding tests which no longer do what they are meant to and developing new ones which provide better assessments of potential human hazards.

### REFERENCES

1. Maugh, T.M., *Science*, **199** (1978), 162.
2. National Research Council, *Toxicity Testing: Strategies to Determine Needs and Priorities*, (National Academy of Sciences, Washington), 1984.
3. Rofe, P.C., *Fd. Cosmet. Toxicol.*, **9** (1971), 683-96.
4. Zbinden, G., *Eur. J. Clin. Pharmacol.*, **9** (1976), 33-38.
5. Heywood, R., *J. Roy. Soc. Med.*, **71** (1978), 686-689.
6. Melmon, K. L., *Clin. Pharmacol. Ther.*, **20** (1976), 125-129.
7. Muul, I., Hegyeli, A.F., Dacdre, J.C., & Woodard, G., *Science*, **193** (1976), 834.
8. Stevenson, D.E., *J. Tox. Env. Hlth.*, **5**(1979), 9-15.
9. Efron, E., *The Apocalypitics: Politics, Science and the Big Cancer Lie*, Simon and Schuster, New York, 1984.
10. Pomerat, C.M. & Leake, D.C., *Ann. N. Y. Acad. Sci.*, **58** (1954), 1110-1128.
11. Worden, A.N., *Tissue culture*. In *Modern Trends in Toxicology.*, E. Boyland, R. Goulding (Eds), (Butterworth, London), **2**, 1974, pp. 216-49.
12. Dawson, M., *Cellular Pharmacology*, (Charles Thomas, Springfield), 1972.
13. Berky, J. & Sherrod, C. (Eds), *In Vitro Toxicity Testing 1975-76*. (Franklin Institute Press, Philadelphia), 1978.
14. Deutsch Pharmakologische Gesellschaft, *Toxicology Symposium. Isolated cell systems as a tool in toxicology research.*, *Arch. Toxicol.*, **44**(1980), 1-210.
15. Zucco, F. & Hooisma, J. (Eds), *Proceedings of the Second International Workshop on the Application of Tissue Culture in Toxicology*, *Toxicol.*, **25** (1982), 1-74.
16. Tardiff, R.G., *Ann. Rev. Pharmacol. Toxicol.*, **18**(1978), 357-369.

17. Nardone, R.M., Toxicity testing *in vitro*. In Growth, Nutrition and Metabolism of Cells in Culture, R.M. Rothblatt & V.J. Cristofala(Eds), (Academic Press, New York), 3 .1977, pp. 471-496.
18. Stammatti, A.P., Silano, V. & Zucco, F., *Toxicol.*, **20** (1981), 91-153.
19. Ekwall, B., Screening of toxic compounds in mammalian cell cultures. In Cellular Systems for Toxicity Testing, G.M. Williams, V. Dunkel, V.A. Ray. (Eds) (Annals of the New York Academy of Sciences), **407**, 1983, pp. 64-77.
20. Grisham, J.W., & Smith, G.J., *Pharmacol. Rev.*, **36** (1984), 151S-175S.
21. Fry, J.R. & Bridges, J.W., The metabolism of xenobiotics in cell suspension and cell culture. In Progress in Drug Metabolism., J.W. Bridges & L.F. Chasseaud(Ed), (J. Wiley and Sons. London), **2**(1977), 71-118.
22. Barnes, D. & Sato, G., *Cell*, **22**(1980), 649-55.
23. Nardone, R.M. & Bradlaw, J.A., *J. Toxicol.-Cut.Ocular Toxicol.*, **2** (1983), 81-98.
24. Goldberg, A.M., *Pharmacol. Rev.*, **36** (1984), 173S-175S.
25. Rowan, A.N., Of Mice, Models and Men: A Critical Analysis of Animal Research, (State University of New York Press, Albany), 1984.
26. Trevan, J.W., *Proc. Roy. Soc. Lond. B.*, **101** (1927), 483-514.
27. Morrison, J.K., Quinton, R.M., & Reinert, M., The purpose and value of LD 50 determinations. In modern Trends in Toxicolog., E. Boyland, R. Goulding(Eds), (J. Wiley and Sons Chichester, **1** (1968), 1-17.
28. Hunter, W.J., Lingk, W. & Recht, P., *J. Assoc. of Anal. Chem.*, **62** (1978), 864-73.
29. Zbinden, G., Flury-Roversi, M., *Arch. Toxicol.*, **47** (1981), 77-99.
30. Rowan, A.N., *Acta Pharmacol Toxicol.*, **52** (Suppl.2), (1983), 52-64.
31. Goldberg, A.M., (Ed), Acute Toxicity Testing : Alternative Approaches, Alternative Methods in Toxicology, (Mary Ann Liebert, New York), Vol. 2 , 1984.
32. Bass, R., Gunzel, P., Henschler, D., Konig, J., Lorke, D., Neubert, D., Schutz, E., Schuppan, D. & Zbinden, G. *Arch. Toxicol.*, **51** (1982), 183-186.
33. Veberla, K. & Schifneders, B., *Aech. Toxicol.*, **51** (1982), 187.
34. Food and Drug Administration, Final Report on Acute Studies Workshop, Office of Science Co-ordination, U.S.Food and Drug Administration, Washington, February 23, 1984.
35. Bruce, R.D., *Fundam. Appl. Toxicol.*, **4** (1984), (in press).
36. Dixon, W.J. & Mood, A.M., *J. Am. Stat. Assoc.*, **43** (1948), 109-126.
37. Tattershall, M.L., *Arch. Toxicol., Suppl.*, **5** (1982), 267-270.
38. Schutz, E. & Fuchs, H., *Arch. Toxicol.*, **51** (1982), 197-200.
39. Muller, H. & Kley, H.P., *Arch. Toxicol.*, **51** (1982), 189-196.
40. Lorke, D., *Arch. Toxicol.*, **54** (1983), 275-287.
41. Deichmann, W.B. & LeBlanc, T.J., *J. Ind. Hyg. Toxicol.*, **25** (1943), 415-417.

42. Enslein, K., Lander, T.R., Tomb, M.E. & Craig, P.N., A predictive model for estimating rat oral LD 50 values, *Benchmark papers in Toxicology*, (Princeton Scientific Publishers, Princeton), Vol. 1, 1983.
43. Enslein, K. & Craig, P.N., *J. Environ. Toxicol.*, **2** (1978), 115-121.
44. Rekker, R.F., *Trends Pharmac. Sci.*, **1** (1980), 383-384.
45. Goldberg, L.(Ed), *Structure-Activity Correlation as a Predictive Tool in Toxicology: Fundamentals, Methods and Applications.*, (Hemisphere Publishing Corporation, Washington), 1983, p. 330.
46. Bariled, M.F. & Hardegee, M., *Proc. Soc. Exp. Biol. Med.*, **133** (1970), 222-228.
47. Autian, J. & Dillingham, E.O., Overview of general toxicity testing with emphasis on special tissue culture tests. *In Vitro Toxicity Testing, 1975-1976*. J. Berky, C. Sherrod, (Eds), (Franklin Institute Press, Philadelphia), 1978, pp 23-49.
48. Sako, F., *Toxicol. Appl. Pharmacol.*, **39** (1977), 111-117.
49. Ekwali, B., *Toxicol.*, **17** (1980), 127-142.
50. Balls, M., Bridges, J.W., The FRAME research program on *in vitro* cytotoxicology. In *Acute Toxicity Testing: Alternative Approaches*, A.M. Goldberg (Ed), (Mary Ann Liebert, New York), 1984, pp. 61-79.
51. Draize, J.H., Woodward, G., & Clavery, H.O., *J. Pharmacol. Exp. Ther.*, **82** (1944), 377-390.
52. Friedenwald, J.S., Hughes, W.F. & Herrmann, H., *Arch. Ophthalmol.*, **31** (1944), 279-283.
53. Weil, C.S., & Scala, R.A., *Toxicol. Appl. Pharmacol.*, **19** (1971), 276-360.
54. Griffith, J.F., Nixon, G.A., Bruce, R.D., Reer, P.J. & Bannan, E.A., 1980., *Toxicol. Appl. Pharmacol.*, **55** (1980), 501-513.
55. Rowan, A.N., *Cosmetic Technol.*, **3** (7), (1981), 32-37.
56. Smyth, D.H. *Alternatives to Animal Experiments*, (Scolar Press, London), 1978, p. 68.
57. Falahee, K.J., Rose, C., Olin, S.S. & Seifried, H.E., Eye irritation testing: an assessment of methods and guidelines for testing materials for eye irritancy, Office of Pesticides and Toxic Substances, U.S. Environmental Protection Agency (EPA-560/11-82-001), Washington, 1981.
58. Walberg, J., *Toxicol. Letts.*, **18** (1983), 49-55.
59. Ulsamer, A.G., Wright, P.L. & Osterberg, R.E., A comparison of the effects of model irritants on anesthetized and nonanesthetized rabbit eyes. *Society of Toxicology*, 16th Annual Meeting, abs. 143, 1977.
60. Johnson, A.W., Use of small dosage and corneal anaesthetic for eye testing *in vivo*. In *Proceedings of the CTFA Ocular Safety Testing Workshop: In vivo and In vitro Approaches*, October 6&7, 1980. Washington: Cosmetic, Toiletry and Fragrance Association, 1980.
61. Williams, S.J., *Fd. Chem. Toxicol.*, **22** (1984), 157-161.
62. Murphy, J.C., Osterberg, R.E., Seabaugh, V.M. & Bierbower, G.W., *Toxicol.*, **23** (1982), 281-291.

63. Walz, D., *Trends Pharmac. Sci.*, **5** (1984), 221-224.
64. Simons, P.J., An alternative to the draize test. In the use of Alternatives in Drug Research, A.N. Rowan, C.J. Stratmann, (Eds), (Macmillan, London), 1980, pp. 147-151.
65. Bell, M., Holmes, P.M., Nisbet, T.M., Uttley, M. & Van Abbe, N.J., *Int. J. Cosmet. Sci.*, **1** (1979), 123-131.
66. Scalfe, M.C., *Int. J. Cosmet. Sci.*, **4** (1982), 179-183.
67. Chan, K.Y., & Haschke, R.H., *Exp. Eye Res.*, **36** (1983), 231-246.
68. McCormack, J.A., Procedure for the *in vitro* evaluation of the eye irritation potential of surfactants. In Trends in Bioassay Methodology: *In vivo in vitro* and Mathematical Approaches, National Institute of Health, Washington, (NIH Pub.No. 82-2382), 1981, pp. 177-186.
69. Burton, A.B.G., York, M. & Lawdrence, R.S., *Fd. Cosmet. Toxicol.*, **19** (1981), 471-480.
70. Shopsis, C. & Sathe, S., *Toxicol.*, **29** (1984), 195-206.
71. Borenfreund, E. & Borrero, O., *Cell-Biol. Toxicol.*, **1** (1984), 33-39.
72. Leighton, J., Nassauer, J., Tchao, R. & Verdone, J., Development of a procedure using the chick egg as an alternative to the Draize rabbit test. In Product Safety Evaluation, A.M. Goldberg (Ed), (Mary Ann Liebert, New York), 1983, pp. 163-177.
73. Muir, C.K., Flowerr, C. & Van Abbe, N.J., *Toxicol. Lett.*, **18** (1983), 1-5.
74. Muir, C.K., *ATLA*, **11** (1984), 129-134.
75. Douglas, W.H.J. & Spilman, S.D., *In vitro* ocular irritancy testing. In Product Safety Evaluation, A.M. Goldberg, (Ed), (Mary Ann Liebert, New York), 1983, pp. 205-230.
76. Silverman, J., *Lab. Animal Sc.*, **33** (1983), 56-59.
77. Carter, L.M., Duncan, G. & Rennie, G.K., *Exp. Eye Res.*, **17** (1973), 409-416.
78. North, Root, H., Yackovitch, F., Demetrulias, J., Gracula, M. & Heinze, J.E., *Toxicol. Letts.*, **14** (1982), 207-212.
79. Jumblatt, M.M. & Neufeldt, A.H., *Invest. Ophthalmol. Vision Sci.*, **24** (Suppl), (1983), 44.
80. Marks, R., Testing for cutaneous toxicity. In Animals and Alternatives in Toxicity Testing, R.J. Riddell, Balls & A.N. Worden (Eds), (Academic Press, London), 1983, pp. 313-327.
81. Kligman, A.M., Assessment of mild irritants. In Principles of Cosmetics for the Dermatologist, P. Frost, & S.N. Horwitz (Eds), (St. Louis: Mosby), 1982, pp. 265-273.
82. Kao, J., Hall, J. & Holland, J.M., *Toxicol. Appl. Pharmacol.*, **68** (1983), 206-217.
83. Fouts, J.R., *Trends in Pharma. Sci.*, **3** (1982), 164-166.
84. Weinberg, E.H. & Springer, S.T., *J. Soc. Cosmet. Chem.*, **32** (1981), 303-315.

85. Tenenbaum, S., Dinardo, J., Morris, W.E., Wolf, B.A. & Schnetzinger, R.W., *Cell Biol. Toxicol.*, **1** (1984), 1-6.
86. McAuliffe, D.J., Morrison, W.L. & Parrish, J.A., An *in vitro* test for predicting the photosensitizing potential of various chemicals. In *Product Safety Evaluation*, A.M. Goldberg (Eds), (Mary Ann Liebert, New York), 1983, pp 285-307.
87. Morrison, W.L., McAuliffe, D.J., Parrish, J.A. & Bloch K.B., *J. Invest. Dermatol.*, **78** (1982), 460-463.
88. Ambesi-Impiombata., F.S., Parks, L.A.M. & Coon, H.G., *Proc. Nat. Acad. Sci.*, **77** (1980), 3455-3459.
89. Miletich, D.J., Khan, A., Albrecht, R.F. & Jozefiak, A., *Toxicol. Appl. Pharmacol.*, **70** (1983), 181-187.
90. Ramos, K., Combs, A.B., & Acosta, D., *Toxicol. Appl. Pharmacol.*, **70** (1983), 317-323.
91. Wold, S., Hellberg, S., & Dunn, W.J., *Acta Pharmacol. Toxicol.*, **52** (1983), 158-189.
92. Craig, P.N., *Ann. Rep. Med. Chem.*, **18** (1983), 303-306.